Seoulin Bioscience Co

Seoulin Bioscience Co Current Liabilities

The Current Liabilities of Seoulin Bioscience Co (038070.KQ) as of Nov 4, 2026 is 7.77 B KRW. In the previous year, Current Liabilities was 9.21 B KRW — a change of -15.70% (lower).

Current Liabilities

7.77 BKRW

YoY

-15.70%

Last updated:

Current Liabilities of Seoulin Bioscience Co is 2025 7.77 B KRW. Current Liabilities of Seoulin Bioscience Co was 2024 9.21 B KRW. It decreases by -15.70% lower compared to the previous year.

The Seoulin Bioscience Co Current Liabilities history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Current Liabilities
Date
Current Liabilities
Jan 1, 2018
13.10 B KRW
Jan 1, 2019
16.18 B KRW
Jan 1, 2020
14.10 B KRW
Jan 1, 2021
12.52 B KRW
Jan 1, 2022
26.71 B KRW
Jan 1, 2023
19.19 B KRW
Jan 1, 2024
9.21 B KRW
Jan 1, 2025
7.77 B KRW
The Seoulin Bioscience Co Current Liabilities history
YEARCurrent LiabilitiesYoY
7.77 BKRW-15.70%
9.21 BKRW-51.99%
19.19 BKRW-28.14%
26.71 BKRW+113.34%
12.52 BKRW-11.22%
14.10 BKRW-12.87%
16.18 BKRW+23.55%
13.10 BKRW+3.82%
12.62 BKRW+11.72%
11.29 BKRW-23.81%
14.82 BKRW-25.63%
19.93 BKRW+117.98%
9.14 BKRW-25.29%
12.24 BKRW—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Seoulin Bioscience Co Stock analysis

What does Seoulin Bioscience Co do? SeouLin Bioscience Co., Ltd. generates revenue through the development and supply of reagents, including DNA chips for gene therapy, clinical diagnosis, organ transplantation, and biopsy, as well as stem cells for treating incurable diseases and Alzheimer's disease. The company markets these products under its brand MyLab and imports bio research equipment from Thermo Fisher, Affymetrix, and Sarstedt for domestic sales. Additionally, SeouLin Bioscience operates a real estate rental business to diversify its income streams. The primary customers for MyLab reagents and stem cell therapies are healthcare providers, research institutions, and medical facilities requiring advanced diagnostic and therapeutic solutions. Domestic market distribution of imported bio research equipment from Thermo Fisher, Affymetrix, and Sarstedt targets laboratories and hospitals seeking high-quality research tools. The real estate rental business serves commercial tenants in Seongnam, Gyeonggi-Do, where the company is headquartered. SeouLin Bioscience focuses on the lifescience sector, specifically targeting applications in gene therapy, clinical diagnostics, and regenerative medicine. Its product segments include DNA chips, stem cells, and next-generation biotechnology drugs, all under the MyLab brand. The company leverages strategic imports of bio research equipment to meet domestic demand for specialized laboratory tools. Seoulin Bioscience Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Seoulin Bioscience Co stock

Current Liabilities of Seoulin Bioscience Co is 7.77 B KRW in 2025.

Current Liabilities of Seoulin Bioscience Co changed from 9.21 B KRW to 7.77 B KRW, representing a -15.70% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Current Liabilities Seoulin Bioscience Co since 2006 – with annual values, charts, and detailed analysis.

Current liabilities are obligations due within one year, including accounts payable, short-term debt, and accrued expenses.

Current Liabilities's KRW is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Current Liabilities's Seoulin Bioscience Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Seoulin Bioscience Co

All Key Metrics — Seoulin Bioscience Co